ARVN Arvinas, Inc.

NASDAQ
$6.76

Arvinas, Inc. (ARVN) Earnings News

Earnings press releases, previews and reviews for Arvinas, Inc. (ARVN), newest first. Our most recent is review: Arvinas Misses as Revenue Resets to Royalties; Cost Cuts and a December BCL6 Readout Matter More Than ARV-102's Latest Delay.

Wednesday November 4, 2026 4:01 PM ET
Arvinas to Present Preliminary Clinical Data from Early Monotherapy Dose Escalation Cohorts in the Phase 1 Trial for ARV-393 (Zaloblideg), a PROTAC BCL6 Degrader, at the 2026 American Society of Hematology (ASH®) Annual Meeting
Tuesday November 3, 2026 10:29 AM ET
Arvinas Misses as Revenue Resets to Royalties; Cost Cuts and a December BCL6 Readout Matter More Than ARV-102's Latest Delay
Earnings Whispers · Review
Tuesday November 3, 2026 7:00 AM ET
Arvinas Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Tuesday October 27, 2026 12:49 PM ET
After Its Vepinu Windfall, Arvinas Must Show a Thinner Pipeline Can Still Deliver
Earnings Whispers · Preview
Tuesday October 27, 2026 7:00 AM ET
Arvinas to Report Third Quarter 2026 Financial Results on November 3, 2026
Wednesday October 7, 2026 7:00 AM ET
Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson’s Disease
Thursday October 1, 2026 4:01 PM ET
Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson’s Disease and Movement Disorders®
Monday September 28, 2026 7:00 AM ET
Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate
Tuesday August 4, 2026 7:00 AM ET
Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Tuesday July 28, 2026 7:00 AM ET
Arvinas to Report Second Quarter 2026 Financial Results on August 4, 2026
Thursday June 4, 2026 8:00 AM ET
Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s Disease
Tuesday May 12, 2026 7:05 AM ET
Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update